CSL's Financial Results
We announced our Full Year Results for the period ending 30th June 2020 on Wednesday, 19th August 2020 (AEST). Please click the link below to view our historic Full Year and Half Year Financial Results.More Information
Search Results198 results found
We will announced our 2020 Half Year Results on Wednesday, 12th February 2020 (AEDT)
CSL Limited Paul Perreault, CEO and MD 2020 Half Year Results David Lamont, CFO 12 February 2020 LEGAL NOTICE Forward looking st...
CSL Limited Paul Perreault, CEO and MD 2020 Half Year Results David Lamont, CFO 12 February 2020 LEGAL NOTICE Forward looking statements The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and products in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL.
CSL's exceptionally strong performance is a result of the focused execution of our strategy. Learn more.
12 February 2020 CSL Delivers a Strong Half Year Result1 Full Year profit guidance upgraded
US$0.93 per share, unfranked, paid on 12 October 2018 for FY18) Dividends determined, but not yet paid at the end of the half-year 431.2 386.5 Interim dividend of US$0.95 per share, unfranked, expected to be paid on 9 April 2020.
CSL Limited ABN: 99 051 588 348 ASX Full-year information 30 June 2020 Lodged with the ASX under Listing Rule 4.3A. Contents
2020 Key Dates 19 August Annual profit and final dividend announcement 10 September Shares traded ex-dividend 11 September Record date for final dividend 9 October Final dividend paid 14 October Annual General Meeting 31 December Half Year ends
The role of CSL's internal audit function is to provide Prior to giving their directors' declaration in respect of the independent and objective assurance to the Audit and Risk annual and half-year financial statements, the Board requires Management Committee and executive management the Managing Director and the Chief Financial Officer to regarding the effectiveness of CSL's risk management each sign a written declaration to the Board, to the effect processes (including the state of any material risks) and that, in their opinion, the financial records of the entity have internal compliance and control systems.
1 Chairman and CEO's Letter 2 CSL Calendar 2 2019 Performance 4 2019 Business performance and highlights 4 14 August Annual profi t and fi nal dividend announcement Financial highlights 5 10 September Shares traded ex-dividend 3 Our Company 6 11 September Record date for fi nal dividend Our businesses 6 Our locations 7 11 October Final dividend paid Our product portfolio 8 16 October Annual General Meeting Our research and development pipeline 9 31 December Half year ends 4 CSL Strategy 10 2020 How we create value 12 12 February Half year profi t and interim dividend 5 Powered by Innovation 14 announcement Collaboration with and funding of medical research 14 11 March Shares traded ex-dividend Investment in research and development pipeline 14 12 March Record date for interim dividend Focus on selected therapeutic areas - specialisation 15 9 April Interim dividend paid New products to market 16 30 June Year ends Clinical trials in process and new 18 19 August Annual profi t and fi nal dividend announcement Clinical trial transparency 18 10 September Shares traded ex-dividend Leveraging advanced analytics and artifi cial intelligence 19 11 September Record date for fi nal dividend Innovation across the value chain 19 9 October Final dividend paid 6 Global Reach and Impact 21 14 October Annual General Meeting Global reach and focus 21 31 December Half year ends Donor management 24 Focus on effi ciency, standardised manufacturing 24 processes and integrated supply chain Annual General Meeting Environment health and safety 25 Wednesday, 16 October 2019 at 1 p.m. Supply chain management 25 7 A Trusted Health Partner 26 New city and venue Product quality and safety 26 Value and access 27 The Westin Sydney, Grand Ballroom Public policy engagement 28 1 Martin Place Secure and reliable supply 29 Sydney NSW 2000 Pandemic and emergency response 29 Relationships with healthcare professionals 29 Share Registry regulators and patient groups Computershare Investor Services Pty Limited Responsible marketing and promotion 29 Postal Address:
11 September Record date for fi nal dividend 9 October Final dividend paid 14 October Annual General Meeting 31 December Half Year ends Find out more 2021 Key Dates CSL.com 16 February Half year profi t and interim dividend announcement 4 March Shares traded ex-dividend About this report 5 March Record date for interim dividend This is CSL's second annual report where we have combined our 1 April Interim dividend paid financial and non-financial performance in one comprehensive 30 June Full Year ends account, linking our sustainability and strategic priorities to our business results.